Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy using SV40-derived vectors: what does the future hold?

D S Strayer1

  • 1Department of Pathology, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. david.strayer@mail.tju.edu

Journal of Cellular Physiology
|October 21, 1999
PubMed
Summary

Simian virus-40 (SV40) shows promise as a gene therapy vector, offering high efficiency and sustained expression without immunogenicity. This recombinant SV40 (rSV40) vector effectively delivers genetic material to target cells, complementing existing gene delivery methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of HtrA2/Omi activity in non-neuronal tissues of adult mice causes premature aging.

Cell death and differentiation·2012
Same author

Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Neuroscience·2012
Same author

Bone marrow-derived cells migrate to line the vessels of the CNS: opportunities for gene delivery to CNS vasculature.

Neuroscience·2011
Same author

Intracisternal rSV40 administration provides effective pan-CNS transgene expression.

Gene therapy·2011
Same author

Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe.

Gene therapy·2011
Same author

In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Gene therapy·2009

Area of Science:

  • Molecular Biology
  • Virology
  • Biotechnology

Background:

  • Gene therapy requires efficient and safe delivery vehicles.
  • Existing viral vectors have limitations such as immunogenicity, low efficiency, and production challenges.
  • Simian virus-40 (SV40) is explored as an alternative vector due to its theoretical advantages.

Purpose of the Study:

  • To evaluate recombinant SV40 (rSV40) as a gene delivery vector for therapeutic applications.
  • To investigate the potential of rSV40 to overcome limitations of other viral vectors.
  • To assess rSV40 efficacy in hematopoietic progenitor cells and liver cells.

Main Methods:

  • Development and characterization of rSV40 vectors.
  • Gene transfer studies in hematopoietic progenitor cells (CD34+) and their derivatives.

Related Experiment Videos

  • Gene delivery experiments in liver cells.
  • In vitro and in vivo efficacy assessments.

    • Main Results:

    • rSV40 vectors are easily produced at high titers, are stable, and lack immunogenicity.
    • Sustained high-level transgene expression is achieved in both resting and dividing cells.
    • rSV40 demonstrated high efficacy in gene transfer to hematopoietic progenitor cells and liver cells, both in vitro and in vivo.
    • The primary limitation of SV40 vectors is the packageable insert size (<=5 kb).

    Conclusions:

    • rSV40 is a highly effective and promising gene delivery vehicle.
    • It offers significant advantages over existing vectors, including high efficiency and low immunogenicity.
    • rSV40 can complement current gene therapy approaches and is suitable for applications involving hematopoietic progenitor cells and liver gene transfer.